A5102732402- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
- CNS Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Chronic Myeloid Leukemia Treatments
- T-cell and Retrovirus Studies
- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- Epigenetics and DNA Methylation
- Biosimilars and Bioanalytical Methods
- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- Integrated Circuits and Semiconductor Failure Analysis
- Colorectal and Anal Carcinomas
- Gastrointestinal Tumor Research and Treatment
- Hepatitis C virus research
- Gastric Cancer Management and Outcomes
- Methemoglobinemia and Tumor Lysis Syndrome
Peking University Cancer Hospital
2015-2024
Peking University
2015-2024
Capital Medical University
2024
Beijing Friendship Hospital
2024
Shanxi Agricultural University
2024
Suzhou Research Institute
2024
Children’s Hospital of Fudan University Xiamen Branch
2023
Xi'an Peihua University
2018
Cancer Research Center
2012
Fred Hutch Cancer Center
2012
Abstract Background: The risk factors for esophageal squamous cell carcinoma (ESCC) in the high-incidence areas of China remain unclear. Methods: A total 300 patients with ESCC and 900 controls matched age sex were enrolled Anyang (China), a high-risk area China. In tumor tissue cases biopsies controls, presence human papillomavirus (HPV) DNA was assessed by an SPF1/GP6+-mediated PCR followed sequencing. serum antibody against HPV-16 E7 oncoprotein use ELISA. ORs 95% confidence intervals...
GLS-010 (zimberelimab) is a novel, fully human, anti-programmed death-1 monoclonal antibody that shows promising efficacy and safety in advanced solid tumors. This trial aimed to evaluate the of Chinese patients with relapsed or refractory classical Hodgkin lymphoma (r/r-cHL).This phase II, single-arm, open-label, multicenter clinical was conducted at 24 centers China enrolled r/r-cHL after two more lines therapy. The were administered intravenous (240 mg, once every 2 weeks) until...
In the phase 3 POLARIX study in previously untreated diffuse large B-cell lymphoma, polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared vincristine, (R-CHOP) similar safety. Patients were randomized 1:1 to 6 cycles of Pola-R-CHP or R-CHOP 2 alone. For registration China, consistency PFS an Asia subpopulation (defined as ≥50% risk reduction expected global population) was...
3008 Background: RIDA is a non-prodrug rapamycin analog mTOR inhibitor, and DALO humanized monoclonal antibody targeting the IGF-1R receptor. In preclinical models, dual mTOR/IGF1-R inhibition results in synergistic antitumor activity inhibits feedback AKT activation due to TORC1 by analogs. Methods: Pts with advanced cancers who failed standard therapy received at escalating doses of 10-40 mg/day QD×5/week combined 10 mg/kg/week or 7.5 mg/kg every other week. was administered for one week...
Abstract Background Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in R/R cHL Methods Transplant-eligible patients with were enrolled received two 14-day cycles 200 mg intravenously (IV) 28-day IV, 1000 mg/m 2 100 IV on days 1 15. Patients partial response (PR) stable disease an additional cycle...
Tislelizumab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody specifically designed to minimize binding Fcγ receptors (FcγR).Here, we present the extended 3-year follow-up of a phase II study tislelizumab in 70 patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who failed or were ineligible for autologous stem transplantation.With median 33.8 months, overall response rate by independent review committee was 87.1%, and complete (CR) 67.1%. Responses...
Relapsed or refractory (r/r) mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a poor prognosis. Bruton tyrosine kinase (BTK) mediator of receptor signaling and associated the development lymphomas. Patients r/r MCL were enrolled in this phase 1/2 study treated orelabrutinib, novel, highly selective BTK inhibitor. The median number prior regimens was 2 (range, 1-4). age 62 years 37-73 years). Eligible patients received oral orelabrutinib 150 mg once daily (n = 86) 100 twice...
Interim 18F-FDG PET/CT is an effective predictor in patients with DLBCL, but the standard evaluating criteria were controversial. In this study, investigators tried to investigate whether liver SUVmax (SUVmax-liver)-based interpretation could improve accuracy of predicting outcomes, comparing Deauville five-point scale (5-PS) and reduction rate maximum standardized uptake value (ΔSUVmax) criteria. 119 patients, after two chemotherapy cycles (PET2) evaluated SUVmax-liver-based interpretation,...
Classical Hodgkin lymphoma (cHL) has been identified with universal genetic alterations of chromosome 9p24.1, which contains <i>PD-L1/PD-L2</i> genes. The amplification 9p24.1 is associated the increased expression <i>PD-L1</i> and <i>PD-L2</i> on RS cells, promotes their immune evasion, subsequently makes cHL sensitive to PD-1 blockade. Several inhibitors have shown significant efficacies overall response rate (ORR) 70%−90% in relapse/refractory (r/r) acquired approvals for this indication....
Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma (PTCL). This phase 1b study evaluated the safety, pharmacokinetics, and preliminary efficacy of chidamide in combination with cyclophosphamide, doxorubicin, vincristine prednisone (CHOP) treatment-naïve PTCL patients.This was open-label, multicenter trial composed dose escalation expansion. Patients received CHOP six 21-d cycles on d 1, 4, 8 11 each cycle. Four...
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Loncastuximab tesirine (Lonca), an antibody conjugate targeting CD19, has demonstrated significant clinical benefit in R/R DLBCL global phase 2 LOTIS-2 study. In the China bridging pivotal OL-ADCT-402-001 study, eligible patients aged ≥18 years who had failed ≥ lines of systemic therapies were enrolled and treated Lonca every 3 week 150 μg/kg for cycles; then 75 subsequent cycles (up to 1...
Limited information is available regarding the patient safety culture in Chinese hospitals. This study aims to assess Peking University Cancer Hospital and identify opportunities for improving organization's culture.A cross-sectional was conducted April 2018 2019, respectively. Data on were collected from clinical administrative staffs using Survey Patient Safety Culture (HSOPSC).Twelve composite dimension variables hierarchically clustered. Three highest positive response dimensions include...
Relapsed/refractory (R/R) classical HL (cHL) and systemic anaplastic large-cell lymphoma (sALCL) treatment options are limited in China. There is a need for new therapies.This single-arm, open-label, multicenter, Phase II study assessed efficacy, safety, pharmacokinetics of single-agent brentuximab vedotin Chinese patients with R/R cHL or sALCL. Patients received 1.8 mg/kg by intravenous infusion on Day 1 3-week cycles (maximum 16 cycles).Patients (N = 39) median 10 (range: 2-16) vedotin....
Background Nearly all anti-PD-1 antibodies are of the IgG4 isotype, and thus possess residual FcR effector functions. Such also associated with immune tolerance escape due to instability CH3 domain Fc-Fc interaction. In this trial, we examined efficacy safety penpulimab, a novel IgG1 antibody that does not bind Fc receptor, in patients refractory or relapsed classical Hodgkin lymphoma (R/R cHL). Methods Adult (≥18 years age) R/R cHL received 200 mg penpulimab once biweekly until disease...
Introduction: Zanubrutinib is a selective and irreversible BTK inhibitor that has demonstrated potent inhibition of in prior studies, with minimal, off-target other kinases. We present updated safety efficacy results from phase 2 study zanubrutinib patients R/R MCL. Methods: In this single-arm, multicenter (ClinicalTrials.gov NCT03206970), oral (160 mg BID) was given to MCL until disease progression (PD) or unacceptable toxicity. Primary endpoint overall response rate (ORR) assessed by an...